To compare non-invasive tests for H. pylori determination (serum, feces, breath test) within one subject with adding a novel feces sample: the fecal immunochemical test (FOB-Gold), used for colorectal cancer screening
ID
Bron
Verkorte titel
Aandoening
Helicobacter pylori, feces sample, urea breath test
Helicobacter pylori, fecestest, ademtest
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
To compare the accuracy of H. pylori determination in FIT with golden standard UBT by assessing: Positivity Rate (PR), Positive Predictive Value (PPV), Negative Predictive Value (NPV), sensitivity and specificity
Achtergrond van het onderzoek
Rationale
Helicobacter pylori (H. pylori) is recognised as a worldwide problem. Asian countries are considered as high risk areas since the majority of the population is still infected with prevalence rates up to 80%. In low risk areas such as the Netherlands prevalence rate is decreasing and is stated around 30%. H. pylori is considered as the starting point of a sequence of several gastric conditions. This sequence leads from H. pylori infection to atrophic gastritis and eventually could end in gastric cancer in 1-2% of the infected patients. It is recommended to eradicate this infection when identified. In high-risk populations, a screen-and-treat method is even proposed. Although, major logistical issues need to be addressed for such a strategy to be widely adopted. There are several noninvasive tests available for the diagnosis of H. pylori infection, of which a stool antigen test (SAT) seems most suitable. This test could indicate an ongoing H. pylori infection and it is easy to perform. However, it is still on debate what type of stool sample is most eligible for the detection of H. pylori infections. Worldwide, screening programs for colorectal cancer (CRC) are already being implemented mostly by using fecal immunochemical tests (FIT). Eligibility of FIT for the diagnosis of H. pylori infection could lead to dual screening of the upper and lower gastrointestinal tract by using the same stool sample and thereby overcome logistic barriers.
Objective: To evaluate the accuracy of H. pylori determination in FIT
Study design
Prospective, proof of concept study
Study population
All patients referred for an urea breath test (UBT) at the Erasmus MC
Intervention
Patients are simultaneously tested by means of UBT, serology, stool antigen assay (SAT), and FIT. Confirmation of eradication will be measured by UBT, SAT and FIT.
Main study parameters/endpoints
Main outcomes are PR, PPV/NPV, and sensitivity/specificity of H. pylori determination in FIT, SAT and serology, compared to UBT as the golden standard
Doel van het onderzoek
To compare non-invasive tests for H. pylori determination (serum, feces, breath test) within one subject with adding a novel feces sample: the fecal immunochemical test (FOB-Gold), used for colorectal cancer screening
Onderzoeksopzet
Feces samples will be sent by mail after which feces collection can be done at home. These samples will be collected on the day of the urea breath test. During breath analysis a single blood sample will be drawn.
After inclusion of 85 patients an interim analysis will be performed. After complete inclusion all analyses will be performed.
Onderzoeksproduct en/of interventie
- 2x feces samples
- 1x vena punction
- 2x questionnaires
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- aged 18 years or older
- referred for urea breath test
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Use of antibiotics/bismuth in the past 4 weeks
- Use of PPI in the past 2 weeks
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL6874 |
NTR-old | NTR7052 |
Ander register | METC Erasmus MC : MEC-2017-528 |